{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:30:13Z","timestamp":1792809013370,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sumitomo Pharma Switzerland GmbH","id":[{"id":"https:\/\/ror.org\/05x9c5966","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022850","name":"Myovant Sciences GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the efficacy and safety of long-term treatment (up to 2\u2009years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>For up to 2\u00a0years, treatment with relugolix CT improved menstrual and non-menstrual pain, dyspareunia, and function in women with endometriosis; after an initial decline of &amp;lt;1%, the mean bone mineral density (BMD) remained stable with continued treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Endometriosis is a chronic condition characterized by symptoms of dysmenorrhea, non-menstrual pelvic pain (NMPP), and dyspareunia, which have a substantial impact on the lives of affected women, their partners, and families. SPIRIT 1 and 2 were phase 3, randomized, double-blind, placebo-controlled studies of once-daily relugolix CT (relugolix 40\u2009mg, oestradiol 1\u2009mg, norethisterone acetate 0.5\u2009mg) in premenopausal women (age 18\u201350\u2009years) with endometriosis and moderate-to-severe dysmenorrhea and NMPP. These trials demonstrated a significant improvement of dysmenorrhea, NMPP, and dyspareunia in women treated with relugolix CT, with minimal decline (&amp;lt;1%) in BMD versus placebo at 24\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>Patients participating in this open-label, single-arm, long-term extension (LTE) study of the 24-week SPIRIT pivotal studies (SPIRIT 1 and 2) received up to an additional 80\u2009weeks of once-daily oral relugolix CT treatment between May 2018 and January 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Premenopausal women with confirmed endometriosis and moderate to severe dysmenorrhea and NMPP who completed the 24-week pivotal studies (SPIRIT 1 and 2 trials; Giudice et al., 2022) and who met all entry criteria were eligible to enrol. Two-year results were analysed by treatment group based on original randomization in pivotal studies: relugolix CT, delayed relugolix CT (relugolix 40\u2009mg monotherapy for 12\u2009weeks, followed by relugolix CT), or placebo\u2192relugolix CT (placebo for 24\u00a0weeks followed by relugolix CT). The primary endpoints of the LTE study were the proportion of dysmenorrhea and NMPP responders at Week 52 and Week 104\/end-of-treatment (EOT). A responder was a participant who achieved a predefined, clinically meaningful reduction from baseline in Numerical Rating Scale (NRS) scores (0\u2009=\u2009no pain, 10\u2009=\u2009worst pain imaginable) for the specific pain type with no increase in analgesic use. The predefined clinically meaningful threshold for dysmenorrhea was 2.8 points and for NMPP was 2.1 points. Secondary efficacy endpoints included change from baseline in Endometriosis Health Profile-30 (EHP-30) pain domain scores, a measure of the effects of endometriosis-associated pain on daily activities (function), NRS scores for dysmenorrhea, NMPP, dyspareunia, and overall pelvic pain, and analgesic\/opioid use. Safety endpoints included adverse events and changes in BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Of 1261 randomized patients, 1044 completed the pivotal studies, 802 enrolled in the LTE, 681 completed 52\u2009weeks of treatment, and 501 completed 104\u2009weeks of treatment. Demographics and baseline characteristics of the extension population were consistent with those of the original randomized population. Among patients randomized to relugolix CT at pivotal study baseline who continued in the LTE (N\u2009=\u2009277), sustained improvements in endometriosis-associated pain were demonstrated through 104\u2009weeks. The proportion of responders at Week 104\/EOT for dysmenorrhea and NMPP was 84.8% and 75.8%, respectively. Decreases in dyspareunia and improvement in function assessed by EHP-30 pain domain were also sustained over 2\u2009years. At Week 104\/EOT, 91% of patients were opioid-free and 75% of patients were analgesic-free. Relugolix CT over 104\u2009weeks was well tolerated with a safety profile consistent with that observed over the first 24\u2009weeks. After initial least squares mean BMD loss &amp;lt;1% at Week 24, BMD plateaued at Week 36 and was sustained for the duration of 104\u2009weeks of treatment. Efficacy and safety results were generally consistent in women in the placebo\u2192relugolix CT and delayed relugolix CT groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>The study was conducted as an open-label study without a control group over the 80\u2009weeks of the extension period. Of the 802 patients who were enrolled in this LTE study, 681 patients (84.9%) and 501 patients (62.5%) of patients completed 52 and 104\u2009weeks of treatment, respectively. In addition, there currently are no comparative data to other hormonal medications. Finally, a third (37.4%) of the study population terminated participation early.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>In conclusion, relugolix CT offers an additional option to help address an important unmet clinical need for effective, safe, and well-tolerated medical treatments for endometriosis that can be used longer-term, reducing the need for opioids and improving quality of life. The findings from this study may help support the care of women with endometriosis seeking longer-term effective medical management of their symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>This study was funded by Myovant Sciences GmbH (now Sumitomo Pharma Switzerland GmbH). C.M.B. reports fees from Myovant, grants from Bayer Healthcare, fees from ObsEva, and Chair of ESHRE Endometriosis Guideline Group (all funds went to the University of Oxford); N.P.J. reports personal fees from Myovant Sciences, during the conduct of the study, personal fees from Guerbet, personal fees from Organon, personal fees from Roche Diagnostics; S.A.-S. reports personal fees from Myovant Sciences, personal fees from Bayer, personal fees from Abbvie, personal fees from UpToDate; J.S.P., and R.B.W. are employees and shareholders of Myovant Sciences; J.C.A.F. and S.J.I. are shareholders of Myovant Sciences (but at time of publicaion are no longer employess of Myovant Sciences); M.S.A. and K.W. have no conflicts to declare; V.M. is a consultant to Myovant; L.C.G. reports personal fees from Myovant Sciences, Inc and Bayer. The authors did not receive compensation for manuscript writing, review, and revision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>NCT03654274.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/dead263","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T08:26:15Z","timestamp":1704443175000},"page":"526-537","source":"Crossref","is-referenced-by-count":60,"title":["Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9870-9581","authenticated-orcid":false,"given":"Christian M","family":"Becker","sequence":"first","affiliation":[{"name":"Nuffield Department of Women\u2019s & Reproductive Health, Endometriosis CaRe Centre, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P","family":"Johnson","sequence":"additional","affiliation":[{"name":"Robinson Research Institute, University of Adelaide , Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"As-Sanie","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Michigan , Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C","family":"Arjona Ferreira","sequence":"additional","affiliation":[{"name":"Myovant Sciences Inc. , Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1320-3010","authenticated-orcid":false,"given":"Mauricio S","family":"Abrao","sequence":"additional","affiliation":[{"name":"Gynecologic Division, A Beneficencia Portuguesa de Sao Paulo , Sao Paulo, Brazil"},{"name":"Obstetrics and Gynecology Department, Faculdade de Medicina FMUSP, Universidade de Sao Paulo , Sao Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wilk","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Department, Boni Fratres Hospital , Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Jung","family":"Imm","sequence":"additional","affiliation":[{"name":"Myovant Sciences Inc. , Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Mathur","sequence":"additional","affiliation":[{"name":"Mathur Consulting LLC , Woodside, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S","family":"Perry","sequence":"additional","affiliation":[{"name":"Myovant Sciences Inc. , Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Wagman","sequence":"additional","affiliation":[{"name":"Myovant Sciences Inc. , Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-0822","authenticated-orcid":false,"given":"Linda C","family":"Giudice","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco , San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2024030111172998800_dead263-B1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the oestrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"2024030111172998800_dead263-B104","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M15-0288","article-title":"Good publication practice for communicating company-sponsored medical research: GPP3","volume":"163","author":"Battisti","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024030111172998800_dead263-B2","doi-asserted-by":"crossref","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","article-title":"ESHRE guideline: endometriosis","volume":"2022","author":"Becker","year":"2022","journal-title":"Hum Reprod Open"},{"key":"2024030111172998800_dead263-B3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.fertnstert.2017.05.004","article-title":"Reevaluating response and failure of medical treatment of endometriosis: a systematic review","volume":"108","author":"Becker","year":"2017","journal-title":"Fertil Steril"},{"key":"2024030111172998800_dead263-B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/humrep\/17.1.221","article-title":"Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age","volume":"17","author":"Cramer","year":"2002","journal-title":"Hum Reprod"},{"key":"2024030111172998800_dead263-B101","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1016\/j.fertnstert.2020.08.248","article-title":"Characterization of pituitary and ovarian hormone concentrations during treatment with relugolix combination therapy","volume":"114","author":"Duijkers","year":"2020","journal-title":"Fertil Steril"},{"key":"2024030111172998800_dead263-B5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/humrep\/det457","article-title":"ESHRE guideline: management of women with endometriosis","volume":"29","author":"Dunselman","year":"2014","journal-title":"Hum Reprod"},{"key":"2024030111172998800_dead263-B6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the oestrogen threshold hypothesis","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2024030111172998800_dead263-B7","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"2024030111172998800_dead263-B8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/humrep\/det050","article-title":"Consensus on current management of endometriosis","volume":"28","author":"Johnson","year":"2013","journal-title":"Hum Reprod"},{"key":"2024030111172998800_dead263-B9","doi-asserted-by":"crossref","first-page":"j3935","DOI":"10.1136\/bmj.j3935","article-title":"Diagnosis and management of endometriosis: summary of NICE guidance","volume":"358","author":"Kuznetsov","year":"2017","journal-title":"BMJ"},{"key":"2024030111172998800_dead263-B10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/AOG.0000000000003267","article-title":"Patterns of prescription opioid use in women with endometriosis: evaluating prolonged use, daily dose, and concomitant use with benzodiazepines","volume":"133","author":"Lamvu","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2024030111172998800_dead263-B102","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-023-01269-9","article-title":"A randomized open-label study of relugolix alone or relugolix combination therapy in premenopausal women","volume":"62","author":"Lukes","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2024030111172998800_dead263-B11","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","article-title":"Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor","volume":"54","author":"Miwa","year":"2011","journal-title":"J Med Chem"},{"key":"2024030111172998800_dead263-B12","author":"MYFEMBREE (Relugolix, Estradiol, and Norethisterone Acetate) Tablets. Prescribing Information"},{"key":"2024030111172998800_dead263-B13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","article-title":"Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice","volume":"723","author":"Nakata","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2024030111172998800_dead263-B14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.fertnstert.2011.05.090","article-title":"Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries","volume":"96","author":"Nnoaham","year":"2011","journal-title":"Fertil Steril"},{"key":"2024030111172998800_dead263-B105","author":"Orilissa (elagolix tablets) Prescribing Information","year":"2018"},{"key":"2024030111172998800_dead263-B15","year":"2019"},{"key":"2024030111172998800_dead263-B16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12905-021-01393-3","article-title":"Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results","volume":"21","author":"Osuga","year":"2021","journal-title":"BMC Womens Health"},{"key":"2024030111172998800_dead263-B17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.fertnstert.2014.02.012","article-title":"Treatment of pelvic pain associated with endometriosis: a committee opinion","volume":"101","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2014","journal-title":"Fertil Steril"},{"key":"2024030111172998800_dead263-B19","year":"2023"},{"key":"2024030111172998800_dead263-B20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jogc.2019.08.004","article-title":"Surgical outcomes in patients with endometriosis: a systematic review","volume":"42","author":"Singh","year":"2020","journal-title":"J Obstet Gynaecol Can"},{"key":"2024030111172998800_dead263-B21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12325-018-0667-3","article-title":"Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States","volume":"35","author":"Soliman","year":"2018","journal-title":"Adv Ther"},{"key":"2024030111172998800_dead263-B22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1515\/CCLM.2006.160","article-title":"Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer","volume":"44","author":"Stricker","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"2024030111172998800_dead263-B103","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2024030111172998800_dead263-B23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2024030111172998800_dead263-B24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1933719110382921","article-title":"Priorities for endometriosis research: a proposed focus on deep dyspareunia","volume":"18","author":"Vercellini","year":"2011","journal-title":"Reprod Sci"},{"key":"2024030111172998800_dead263-B25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-018-0008-5","article-title":"Endometriosis","volume":"4","author":"Zondervan","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024030111172998800_dead263-B26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis","volume":"382","author":"Zondervan","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/3\/526\/56808437\/dead263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/3\/526\/56808437\/dead263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:21:05Z","timestamp":1709274065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/3\/526\/7577817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dead263","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,1,18]]}}}